SynthesisJournal of neurochemistry2025
Common miRNAs, Genes, and Regulatory Pathways in Alzheimer's Disease and Type 2 Diabetes Mellitus: An Integrative Analysis of Systematic Reviews, Bioinformatics and Data Mining.
Synthesis in Journal of neurochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Early blood DNA methylation patterns associated with glycemic progression in a prospective Indian cohort.Clinical epigenetics · 2026Article
- Exosomal MicroRNAs as theranostic tools in type 2 diabetes and its complications: mechanistic insights and clinical implications.Diabetology & metabolic syndrome · 2026Review
- Propyl Gallate Attenuates Methylglyoxal-Induced Alzheimer-like Cognitive Deficits and Neuroinflammation in Mice.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) are frequent conditions affecting older adults, with evidence suggesting a higher predisposition for AD in diabetic patients. MicroRNAs (miRNAs) are proposed as regulators of gene expression in the mutual pathways among these diseases. This study aimed to investigate circulating miRNAs found to be expressed both in AD and T2DM, as well as their target genes and associated molecular pathways, using systematic reviews (SRs), bioinformatics analyses, and data mining. Two independent SRs were conducted to identify differentially expressed miRNAs in AD and T2DM compared to their respective controls. Searches covered major databases (EMBASE, PubMed, Cochrane, Scopus, Cinahl, Web of Science), gray literature, and reference lists, following the Joanna Briggs Institute (JBI) and PRISMA guidelines. Results were combined to identify miRNAs shared by both AD and T2DM, with target genes extracted from miRTarBase. Pathway enrichment analysis was performed using EnrichR, and relevant pathways were ranked based on gene involvement frequency with artificial intelligence tools. From the SRs (AD: 49 studies; T2DM: 104 studies), 21 miRNAs were identified as commonly expressed (10 upregulated, and 11 downregulated). 337 and 233 genes are potential targets for these down- and upregulated miRNAs, respectively. The key pathways identified from those genes were the TCR-RAS signaling cascade for downregulated miRNAs and the extracellular matrix pathway for upregulated miRNAs. Our findings highlight shared biological pathways between AD and T2DM and provide insights into their shared pathophysiology and potential therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.